Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
56
IDXX Quote, Financials, Valuation and Earnings
Last price:
$676.60
Seasonality move
:
4.32%
Day range:
$680.88 - $687.83
52-week range:
$356.14 - $769.98
Dividend yield:
0%
P/E ratio:
54.09x
P/S ratio:
13.35x
P/B ratio:
34.90x
Volume:
432.4K
Avg. volume:
588.5K
1-year change:
65.31%
Market cap:
$54.5B
Revenue:
$3.9B
EPS (TTM):
$12.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IDXX
IDEXX Laboratories, Inc.
|
$1.1B | $2.93 | 12.37% | 11.93% | $766.00 |
|
AMGN
Amgen, Inc.
|
$9.5B | $4.74 | 4.54% | 310.03% | $325.88 |
|
MRNA
Moderna, Inc.
|
$633.1M | -$2.76 | -34.46% | -5.24% | $36.75 |
|
PFE
Pfizer Inc.
|
$16.9B | $0.56 | -4.58% | 694.41% | $28.62 |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$3.2B | $5.17 | 10.21% | 47.45% | $491.92 |
|
ZTS
Zoetis, Inc.
|
$2.4B | $1.40 | 1.91% | 8.81% | $158.22 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IDXX
IDEXX Laboratories, Inc.
|
$682.32 | $766.00 | $54.5B | 54.09x | $0.00 | 0% | 13.35x |
|
AMGN
Amgen, Inc.
|
$328.69 | $325.88 | $177B | 25.41x | $2.38 | 2.9% | 4.96x |
|
MRNA
Moderna, Inc.
|
$30.41 | $36.75 | $11.9B | -- | $0.00 | 0% | 5.28x |
|
PFE
Pfizer Inc.
|
$24.99 | $28.62 | $142.1B | 14.57x | $0.43 | 6.88% | 2.27x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$453.74 | $491.92 | $115.1B | 31.98x | $0.00 | 0% | 10.02x |
|
ZTS
Zoetis, Inc.
|
$126.41 | $158.22 | $55.7B | 21.30x | $0.50 | 1.58% | 6.01x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IDXX
IDEXX Laboratories, Inc.
|
41.62% | 1.034 | 2.18% | 0.69x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
MRNA
Moderna, Inc.
|
7.29% | 0.934 | 7.28% | 3.30x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
9.58% | -0.151 | 1.84% | 1.84x |
|
ZTS
Zoetis, Inc.
|
57.4% | 0.508 | 11.26% | 2.02x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IDXX
IDEXX Laboratories, Inc.
|
$685.3M | $356.8M | 39.29% | 66.88% | 32.28% | $357.9M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
MRNA
Moderna, Inc.
|
$757M | -$260M | -27.85% | -30.18% | -25.59% | -$880M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$2.7B | $1.3B | 20.08% | 22.13% | 41.02% | $1.1B |
|
ZTS
Zoetis, Inc.
|
$1.7B | $936M | 22.32% | 52.95% | 39% | $805M |
IDEXX Laboratories, Inc. vs. Competitors
-
Which has Higher Returns IDXX or AMGN?
Amgen, Inc. has a net margin of 24.85% compared to IDEXX Laboratories, Inc.'s net margin of 33.55%. IDEXX Laboratories, Inc.'s return on equity of 66.88% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital IDXXIDEXX Laboratories, Inc.62.01% $3.40 $2.7B AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About IDXX or AMGN?
IDEXX Laboratories, Inc. has a consensus price target of $766.00, signalling upside risk potential of 12.26%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could fall by -0.85%. Given that IDEXX Laboratories, Inc. has higher upside potential than Amgen, Inc., analysts believe IDEXX Laboratories, Inc. is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXXIDEXX Laboratories, Inc.5 5 1 AMGNAmgen, Inc.10 15 2 -
Is IDXX or AMGN More Risky?
IDEXX Laboratories, Inc. has a beta of 1.668, which suggesting that the stock is 66.77% more volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock IDXX or AMGN?
IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.9% to investors and pays a quarterly dividend of $2.38 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.
-
Which has Better Financial Ratios IDXX or AMGN?
IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. IDEXX Laboratories, Inc.'s net income of $274.6M is lower than Amgen, Inc.'s net income of $3.2B. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 54.09x while Amgen, Inc.'s PE ratio is 25.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 13.35x versus 4.96x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXXIDEXX Laboratories, Inc.13.35x 54.09x $1.1B $274.6M AMGNAmgen, Inc.4.96x 25.41x $9.6B $3.2B
-
Which has Higher Returns IDXX or MRNA?
Moderna, Inc. has a net margin of 24.85% compared to IDEXX Laboratories, Inc.'s net margin of -19.69%. IDEXX Laboratories, Inc.'s return on equity of 66.88% beat Moderna, Inc.'s return on equity of -30.18%.
Company Gross Margin Earnings Per Share Invested Capital IDXXIDEXX Laboratories, Inc.62.01% $3.40 $2.7B MRNAModerna, Inc.74.51% -$0.51 $10.1B -
What do Analysts Say About IDXX or MRNA?
IDEXX Laboratories, Inc. has a consensus price target of $766.00, signalling upside risk potential of 12.26%. On the other hand Moderna, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 20.85%. Given that Moderna, Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Moderna, Inc. is more attractive than IDEXX Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXXIDEXX Laboratories, Inc.5 5 1 MRNAModerna, Inc.3 16 1 -
Is IDXX or MRNA More Risky?
IDEXX Laboratories, Inc. has a beta of 1.668, which suggesting that the stock is 66.77% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.
-
Which is a Better Dividend Stock IDXX or MRNA?
IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDXX or MRNA?
IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are larger than Moderna, Inc. quarterly revenues of $1B. IDEXX Laboratories, Inc.'s net income of $274.6M is higher than Moderna, Inc.'s net income of -$200M. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 54.09x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 13.35x versus 5.28x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXXIDEXX Laboratories, Inc.13.35x 54.09x $1.1B $274.6M MRNAModerna, Inc.5.28x -- $1B -$200M
-
Which has Higher Returns IDXX or PFE?
Pfizer Inc. has a net margin of 24.85% compared to IDEXX Laboratories, Inc.'s net margin of 21.32%. IDEXX Laboratories, Inc.'s return on equity of 66.88% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital IDXXIDEXX Laboratories, Inc.62.01% $3.40 $2.7B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About IDXX or PFE?
IDEXX Laboratories, Inc. has a consensus price target of $766.00, signalling upside risk potential of 12.26%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.54%. Given that Pfizer Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Pfizer Inc. is more attractive than IDEXX Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXXIDEXX Laboratories, Inc.5 5 1 PFEPfizer Inc.7 15 1 -
Is IDXX or PFE More Risky?
IDEXX Laboratories, Inc. has a beta of 1.668, which suggesting that the stock is 66.77% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock IDXX or PFE?
IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.88% to investors and pays a quarterly dividend of $0.43 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios IDXX or PFE?
IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. IDEXX Laboratories, Inc.'s net income of $274.6M is lower than Pfizer Inc.'s net income of $3.6B. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 54.09x while Pfizer Inc.'s PE ratio is 14.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 13.35x versus 2.27x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXXIDEXX Laboratories, Inc.13.35x 54.09x $1.1B $274.6M PFEPfizer Inc.2.27x 14.57x $16.7B $3.6B
-
Which has Higher Returns IDXX or VRTX?
Vertex Pharmaceuticals, Inc. has a net margin of 24.85% compared to IDEXX Laboratories, Inc.'s net margin of 34.76%. IDEXX Laboratories, Inc.'s return on equity of 66.88% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.
Company Gross Margin Earnings Per Share Invested Capital IDXXIDEXX Laboratories, Inc.62.01% $3.40 $2.7B VRTXVertex Pharmaceuticals, Inc.86.69% $4.20 $19.2B -
What do Analysts Say About IDXX or VRTX?
IDEXX Laboratories, Inc. has a consensus price target of $766.00, signalling upside risk potential of 12.26%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 8.41%. Given that IDEXX Laboratories, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe IDEXX Laboratories, Inc. is more attractive than Vertex Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXXIDEXX Laboratories, Inc.5 5 1 VRTXVertex Pharmaceuticals, Inc.17 10 1 -
Is IDXX or VRTX More Risky?
IDEXX Laboratories, Inc. has a beta of 1.668, which suggesting that the stock is 66.77% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.
-
Which is a Better Dividend Stock IDXX or VRTX?
IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDXX or VRTX?
IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. IDEXX Laboratories, Inc.'s net income of $274.6M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 54.09x while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 13.35x versus 10.02x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXXIDEXX Laboratories, Inc.13.35x 54.09x $1.1B $274.6M VRTXVertex Pharmaceuticals, Inc.10.02x 31.98x $3.1B $1.1B
-
Which has Higher Returns IDXX or ZTS?
Zoetis, Inc. has a net margin of 24.85% compared to IDEXX Laboratories, Inc.'s net margin of 30.04%. IDEXX Laboratories, Inc.'s return on equity of 66.88% beat Zoetis, Inc.'s return on equity of 52.95%.
Company Gross Margin Earnings Per Share Invested Capital IDXXIDEXX Laboratories, Inc.62.01% $3.40 $2.7B ZTSZoetis, Inc.70.21% $1.63 $12.7B -
What do Analysts Say About IDXX or ZTS?
IDEXX Laboratories, Inc. has a consensus price target of $766.00, signalling upside risk potential of 12.26%. On the other hand Zoetis, Inc. has an analysts' consensus of $158.22 which suggests that it could grow by 25.16%. Given that Zoetis, Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Zoetis, Inc. is more attractive than IDEXX Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXXIDEXX Laboratories, Inc.5 5 1 ZTSZoetis, Inc.7 8 0 -
Is IDXX or ZTS More Risky?
IDEXX Laboratories, Inc. has a beta of 1.668, which suggesting that the stock is 66.77% more volatile than S&P 500. In comparison Zoetis, Inc. has a beta of 0.972, suggesting its less volatile than the S&P 500 by 2.841%.
-
Which is a Better Dividend Stock IDXX or ZTS?
IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis, Inc. offers a yield of 1.58% to investors and pays a quarterly dividend of $0.50 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Zoetis, Inc. pays out 32.86% of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IDXX or ZTS?
IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are smaller than Zoetis, Inc. quarterly revenues of $2.4B. IDEXX Laboratories, Inc.'s net income of $274.6M is lower than Zoetis, Inc.'s net income of $721M. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 54.09x while Zoetis, Inc.'s PE ratio is 21.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 13.35x versus 6.01x for Zoetis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXXIDEXX Laboratories, Inc.13.35x 54.09x $1.1B $274.6M ZTSZoetis, Inc.6.01x 21.30x $2.4B $721M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
FTAI alert for Dec 31
FTAI Aviation Ltd. [FTAI] is down 0.38% over the past day.
Sell
45
LYEL alert for Dec 31
Lyell Immunopharma, Inc. [LYEL] is down 2.63% over the past day.
Sell
36
CORT alert for Dec 31
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
